Aldehyde Trapping Agents for Dry Eye Disease Biomarker Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease lack effective biomarkers for assessing treatment efficacy and patient selection, leading to inadequate management of ocular inflammation and discomfort.
Innovation Solution
The use of aldehyde markers of oxidative stress, particularly malondialdehyde and 4-hydroxynonenal, as biomarkers to assess the effectiveness of aldehyde trapping agents like reproxalap in treating dry eye disease and ocular inflammation, involving measurement before and after treatment to adjust dosing frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current treatments for dry eye disease are used, then ocular discomfort and inflammation are addressed, but effective biomarkers for assessing treatment efficacy and patient selection are lacking
Solution Approach 1:
The patent measures aldehyde marker levels before treatment begins, establishing a baseline that enables subsequent assessment of treatment efficacy. This preliminary measurement approach allows clinicians to evaluate whether the treatment is working by comparing post-treatment levels against the pre-treatment baseline, thereby solving the lack of biomarkers for efficacy assessment.
Solution Approach 2:
The patent implements a feedback mechanism where aldehyde marker levels are measured both before and after treatment, and this information is used to adjust dosing frequency. The feedback loop (measurement → evaluation → dosing adjustment → re-measurement) enables personalized treatment optimization and provides concrete biomarker-based efficacy assessment that was previously unavailable.
2Adaptability or versatility
If aldehyde trapping agents are used to treat dry eye disease, then ocular inflammation is reduced, but dosing frequency needs to be optimized for individual patients
Solution Approach 1:
The patent changes the dosing frequency parameter based on measured aldehyde marker levels. Patients with greater than 20% reduction in aldehyde markers receive lower dosing frequency, while those with 20% or less reduction maintain the same or increase dosing frequency. This dynamic parameter adjustment enables personalized treatment that adapts to individual patient response without requiring complex treatment protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for personalized treatment regimens, reducing ocular discomfort and inflammation by correlating decreases in aldehyde markers with symptom improvement, enabling more effective management of dry eye disease.
Implementation Method 1
aldehyde trapping agent is reproxalap... measuring the level of an aldehyde marker of oxidative stress... a reduction in level of aldehyde marker of oxidative stress indicates effectiveness
Data Source
AI summary
The present invention relates to use of biomarkers of dry eye disease, and use of the biomarkers for selection of subjects for treatment and treatment of dry eye disease.